AI-enabled clinical intelligence for chronic disease care
Clinical intelligence for earlier action in cardio-renal-metabolic care
Cardiomnis AI is building a clinical intelligence platform that helps healthcare organisations identify high-risk patients earlier, close guideline-based care gaps and coordinate preventive action.
Our initial focus is chronic kidney disease detection-to-prevention for people living with type 2 diabetes and hypertension.
Designed for hospitals, diabetes clinics, nephrology practices, diagnostic laboratories and healthcare research partners.
Platform currently under development and clinical validation.
The care-delivery challenge
Chronic disease risk is often visible before it becomes actionable
People living with type 2 diabetes and hypertension are at increased risk of developing chronic kidney and cardiovascular complications.
Yet important information is frequently distributed across laboratory systems, electronic health records, prescriptions, clinical notes and previous encounters. Missing kidney screening, delayed review, fragmented follow-up and inconsistent referral pathways can allow preventable risks to progress unnoticed.
Healthcare teams do not necessarily need more data. They need clearer priorities, better-connected workflows and timely opportunities to act.
Fragmented clinical information
Relevant laboratory results, medications, comorbidities and previous encounters may sit across disconnected systems.
Incomplete screening
Important kidney-health assessments such as eGFR and urine albumin testing may be missing, delayed or insufficiently followed up.
Delayed prioritisation
Clinicians may lack a simple way to identify which patients require immediate review, closer monitoring or specialist referral.
Unclosed care gaps
A risk may be recognised without a reliable workflow to ensure that testing, treatment review, referral and follow-up are completed.
The Cardiomnis approach
From risk identification to coordinated prevention
Cardiomnis AI is being designed as a workflow-oriented clinical intelligence platform—not simply a prediction score.
The platform aims to convert longitudinal clinical information into prioritised, explainable and actionable insights that support healthcare professionals throughout the detection-to-prevention pathway.
Risk stratification
Identify patients who may require closer kidney and cardio-renal assessment based on available clinical and longitudinal data.
Screening-gap detection
Highlight missing or overdue tests and assessments relevant to kidney-health monitoring.
Patient prioritisation
Organise patient populations according to urgency, care gaps and potential need for intervention.
Referral intelligence
Support more timely and appropriate nephrology review by identifying patients who may benefit from specialist assessment.
Medication-safety support
Surface clinically relevant medication-review considerations for authorised healthcare professionals.
Follow-up orchestration
Help care teams track whether recommended testing, clinical review, referral and follow-up actions have been completed.
Population dashboards
Give healthcare organisations a clearer view of risk distribution, screening completion and unresolved care gaps across their populations.
Outcomes measurement
Support evaluation of screening, referral, follow-up and care-process improvements over time.
First clinical pathway
CKD detection-to-prevention
Cardiomnis AI’s first clinical pathway focuses on chronic kidney disease risk among people living with type 2 diabetes and hypertension.
The objective is to support earlier identification, more complete kidney-health assessment and better coordination between diabetes care, primary care, nephrology, laboratory services and population-health teams.
- 1
Identify
Bring together relevant patient information from approved clinical and administrative sources.
- 2
Assess
Analyse available risk factors, kidney-function trends, albuminuria information, medications and care history.
- 3
Prioritise
Highlight patients who may require missing tests, clinical review, closer follow-up or specialist assessment.
- 4
Support action
Present appropriate workflow prompts and care-gap information to authorised healthcare professionals.
- 5
Track
Monitor whether recommended actions and follow-up steps have been completed.
- 6
Measure
Help organisations evaluate improvements in screening, referral, follow-up and care delivery.
Intelligence that fits into clinical workflows
Cardiomnis AI is being designed to complement existing healthcare systems rather than create another disconnected application.
Connect
Work with approved information from electronic health records, laboratory systems, medication records, health assessments and other authorised sources.
Understand
Build a longitudinal view of patient risk, clinical history and unresolved care needs.
Prioritise
Identify patients and care gaps requiring attention.
Support decisions
Provide explainable information and workflow guidance to qualified healthcare professionals.
Coordinate
Support testing, referral, review and follow-up processes across the care pathway.
Evaluate
Measure care-process performance and population-level outcomes.
Available capabilities and integrations will depend on the deployment, data availability, institutional requirements and applicable regulatory approvals.
Built for organisations responsible for chronic disease outcomes
Responsible development
Built around responsible clinical use
Clinical intelligence must be trustworthy, explainable and used within appropriate professional oversight.
Cardiomnis AI’s development approach is centred on human-in-the-loop decision support, privacy-conscious data use, transparent performance evaluation and validation in relevant healthcare settings.
- Clinical decision support—not autonomous medical practice
- Cardiomnis AI is intended to support qualified healthcare professionals. It is not intended to replace clinical judgement or independently diagnose, prescribe or provide emergency medical care.
- Explainable information
- Insights should be accompanied by relevant clinical factors, data limitations and context required for professional interpretation.
- Validation before scale
- Models and workflows should be evaluated using appropriate retrospective and prospective validation before broader clinical deployment.
- Privacy and security by design
- Data collection, access and processing should be limited to authorised purposes and governed by appropriate technical, contractual and organisational safeguards.
- Human oversight
- Clinical decisions remain with appropriately qualified healthcare professionals and authorised healthcare organisations.
- Performance monitoring
- Deployed systems should be monitored for data drift, model performance, unintended bias and workflow-related risks.
These are the principles guiding our development approach—not claims of existing certifications.
Help shape the future of preventive chronic disease care
Cardiomnis AI is seeking clinical, laboratory, hospital and research partners interested in developing and validating practical chronic disease intelligence workflows.
Partnerships may include workflow discovery, retrospective data studies, clinical pathway design, prospective pilots, usability evaluation and outcomes measurement, subject to appropriate approvals and agreements.
Relevant partners
- Hospitals and health systems
- Diabetes and hypertension clinics
- Nephrology practices
- Diagnostic laboratory networks
- Academic medical centres
- Public-health organisations
- Healthcare payers and employers
- Pharmaceutical and clinical research organisations
Frequently asked questions
Common questions about Cardiomnis AI, our clinical focus and how to work with us.
Cardiomnis AI is a health technology company developing AI-enabled clinical intelligence and workflow solutions for chronic disease care.
Our initial focus is supporting chronic kidney disease detection-to-prevention for people living with type 2 diabetes and hypertension.
No. Cardiomnis AI is being developed as clinical decision-support and workflow technology for use by qualified professionals and authorised organisations. It does not replace professional medical judgement.
The platform is being designed for hospitals, diabetes and primary-care clinics, nephrology practices, diagnostic laboratories, healthcare programmes and research partners.
The platform is under development and validation. Cardiomnis AI is currently exploring design partnerships, research collaborations and pilot opportunities.
No. Cardiomnis AI does not provide individual medical consultation, diagnosis, treatment or emergency services through this website.
No. Visitors should not submit medical records, patient-identifiable information or sensitive health information through the public website.